arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IOVANCE BIOTHERAPEUTICS, INC.

IOVA
$7.72 ▼ -1.01 (-11.62%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

IOVANCE BIOTHERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.5M
Dividend Yield —
Revenue Growth 65.7% ↗
Op. Margin -52.3% ↗
ROIC -6.9% ↗
FCF / Share $-147.23 ↗
Trailing P/E —
Price / Book 4.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$99.31M
↑ +65.7% —
Net Income Profit after all expenses
$-47.31M
↑ +57.6% —
Operating Margin Operating profit as % of sales
-52.3%
↑ +53.9% 1th
FCF / Share Free cash flow per share
$-147.23
↑ +21.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
2
Returns →
15
Cash Quality ↑
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 19 years · 68 quarters